Download PDF
Thromb Haemost 1985; 54(02): 415-417
DOI: 10.1055/s-0038-1657862
Original Article
Schattauer GmbH Stuttgart

Antithrombin III Activity and Concentration in Diabetes Mellitus

G M Patrassi
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
,
R Picchinenna
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
,
R Vettor
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
,
G Cappellato
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
,
D Coccarielli
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
,
A Girolami
The Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School Padua, Italy
› Author Affiliations
Further Information

Publication History

Received 13 February 1985

Accepted 24 April 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Antithrombin III (AT III) levels have been reported to be low, normal, and high in diabetes mellitus. Furthermore, a dicrepancy between AT III activity and antigen concentration was reported. We have evaluated the behaviour of AT III activity and antigen level both in type 1 and type 2 diabetes, either in uncontrolled or in well controlled patients. AT III activity and antigen levels showed values similar to normal. No difference was seen between type 1 and type 2 diabetes. Similar results were observed in the group of well controlled diabetic patients. AT III activity and antigen did not correlate with blood glucose and glycosylated haemoglobin (HbA1). No difference was observed between AT III activity and antigen levels in any group. Therefore the hypercoagulable state found in diabetes mellitus does not depend on AT III modifications. A discrepancy between AT III activity and antigen was not confirmed. A dysantithrombinaemia, explained on the basis of an inactivation of protein glycosylation in diabetes mellitus has not been confirmed.

Keywords

Antithrombin III activity and antigen - Glycosylated haemoglobin - Diabetes mellitus
 

  • References

  • 1 Rosemberg RO. Actions and interactions of antithrombin and heparin. N Eng J Med 1975; 292: 146-151
    CrossrefPubMedGoogle Scholar
  • 2 Filip DI, Eckstein JD, Veltkamp JJ. Hereditary antithrombin deficiency and thromboembolic disease. Am J Haematol 1976; 2: 343-349
    PubMedGoogle Scholar
  • 3 Mackie M, Bennett B, Ogston D, Douglas AS. Familial thrombosis: inherited deficiency of antithrombin III. Br Med J 1978; 32: 136-138
    PubMedGoogle Scholar
  • 4 Matsuo T, Ohki V, Kado S, Matsuo O. Familial antithrombin III deficiency in a Japanese family. Thromb Res 1979; 16: 815-823
    CrossrefPubMedGoogle Scholar
  • 5 Sas G, Blaskó G, Bánhegyi D, Jákó J, Pálos AC. Abnormal antithrombin III (Antithrombin III Budapest) as a cause of a familial thrombophilia. Thrombos Diathes Haemorrh 1974; 32: 105-115
    PubMedGoogle Scholar
  • 6 Girolami A, Marafioti F, Rubertelli M, Vicarioto MA, Cappellato G, Mazzuccato M. Antithrombin III Trento. A “new” congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Acta Haematol 1984; 72: 73-82
    CrossrefPubMedGoogle Scholar
  • 7 Girolami A, Pengo V, Cappellato G, Vianello C, Procidano M, Cartei C. Antithrombin III Padua: a “new” congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol 1983; 110: 98-111
    PubMedGoogle Scholar
  • 8 Girolami A, Fabris F, Cappellato G, Sainati L, Boeri G. Antithrombin III (AT III) Padua2: A “new” congenital abnormality with defective heparin cofactor activities but no thrombotic disease. Blut 1983; 47: 93-103
    CrossrefPubMedGoogle Scholar
  • 9 Sas G, Köves A, Petö I, Domján G. On the inheritance of the abnormal antithrombin III (AT-III Budapest). Thromb Haemostas 1978; 39: 530-532
    PubMedGoogle Scholar
  • 10 Jones RL, Peterson CM. Hematologic alterations in Diabetes mellitus. Am J Med 1981; 70: 339-352
    CrossrefPubMedGoogle Scholar
  • 11 Preston FE. Disorders of haemostasis in Diabetes mellitus. Ricerca Clin Lab 1982; 12: 425-438
    PubMedGoogle Scholar
  • 12 Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lexis D, Bloom A. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983; 9: 254-259
    PubMedGoogle Scholar
  • 13 Patrassi GM, Vettor R, Padovan D, Girolami A. Contact phase of blood coagulation in Diabetes mellitus. Europ J Clin Invest 1982; 12: 307-311
    CrossrefPubMedGoogle Scholar
  • 14 Banerjee RN, Sahni AL, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thrombos Diathes Haemorrh 1974; 31: 339-345
    PubMedGoogle Scholar
  • 15 Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, Pietrantuono C, Rosato GB. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report. Thromb Haemostas 1983; 50: 633-634
    PubMedGoogle Scholar
  • 16 Gandolfo GM, De Angelis A, Torresi MV. Determination of antithrombin III activity by different methods in diabetic patients. Haemostasis 1980; 9: 15-19
    PubMedGoogle Scholar
  • 17 Christe M, Fritschi J, Lämmle B, Tran TH, Marbert GA, Berger W, Duckert F. Fifteen coagulation and fibrinolysis parameters in Diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 138-143
    PubMedGoogle Scholar
  • 18 Elder GE, Mayne EE, Daly JG, Kennedy AC, Hadden DR, Montgomery DAD, Weaver JA. Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. Haemostasis 1980; 9: 288-296
    PubMedGoogle Scholar
  • 19 Grignani G, Gamba G, Geroldi D, Pacchiarini L, Solerte B, Ferrari E, Ascari E. Enhanced antithrombin mechanisms in patients with maturity-onset diabetes mellitus without thromboembolic complications. Thromb Haemostas 1981; 46: 648-651
    PubMedGoogle Scholar
  • 20 Gamba G, Grignani G, Montera V, Perotti G, Ragone L, Ascari E. Activators and inhibitors of the fibrinolytic system in maturity-onset diabetes mellitus without thromboembolic complications. Ricerca Clin Lab 1983; 13: 337-345
    PubMedGoogle Scholar
  • 21 Borsey DQ, Prowse CV, Gray RS, Dawers J, James K, Elton RA. Platelet and coagulation factors in proliferative diabetic retinopathy. J Clin Pathol 1984; 37: 659-664
    CrossrefPubMedGoogle Scholar
  • 22 Abildgaard U, Lie M, Odegaard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
    CrossrefPubMedGoogle Scholar
  • 23 Laurell CB. Quantitative estimation of proteins by electrophoresis of some human proteins. Anal Biochem 1966; 15: 45-52
    CrossrefPubMedGoogle Scholar
  • 24 Mancini G, Carbonara O, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-254
    CrossrefPubMedGoogle Scholar
  • 25 Werner W, Rey H, Wielinger H. Über die Eigenschaften eines neuen Chromogens für die Blutzuckerbestimmung nach der GOD/POD-Methode. Z Analyt Chem 1980; 252: 224-227
    PubMedGoogle Scholar
  • 26 Trivelli LA, Ranne YHM, Lay HT. Haemoglobin components in patients with diabetes mellitus. N Eng J Med 1971; 284: 353-357
    CrossrefPubMedGoogle Scholar
  • 27 Corbella E, Miragliotta G, Maspery R, Villa S, Bini A, De Gaetano G, Chiumello G. Platelet aggregation and AT III levels in diabetic children. Haemostasis 1979; 8: 30-37
    PubMedGoogle Scholar
  • 28 Bunn HF. Nonenzymatic glycosylation of protein: relevance to Diabetes. Am J Med 1981; 70: 325-330
    CrossrefPubMedGoogle Scholar
  • 29 Czech A, Taton J. Glycosylated Hemoglobin (HbA1) as an indicator of therapy effects in different clinical types of diabetes. J Chron Dis 1983; 36: 803-810
    CrossrefPubMedGoogle Scholar
  • 30 Ceriello A, Curcio F, Dello Russo P, Giugliano D. Non-enzymatic glycosylation reduces antithrombin III activity. Thromb Haemostas 1984; 52: 363
    PubMedGoogle Scholar